[Comparative in vitro study of the effectiveness of various immunomodulating substances in tick-borne encephalitis].
Krylova. N V NV; Leonova. G N GN
Key Findings
- TBE virus reduces expression of lymphocyte receptors in vitro
- Anti‑TBE immunoglobulin, 4‑iodantipyrin, and leukinferon gave the best preventive protection
- Thymalin combined with interferon was most effective in treatment‑like conditions
Practical Outcomes
- Thymalin may help the immune system fight TBE when used with interferon, but there’s no human dosing or safety data yet. For biohackers, it’s an interesting experimental candidate, not a ready‑to‑use protocol. More clinical research is needed before recommending it for real‑world use.
Summary
The study tested 14 immune‑boosting compounds on cells infected with tick‑borne encephalitis virus. It found that the virus lowers certain immune‑cell receptors, but some drugs can protect or restore them. Thymalin, especially when paired with human interferon, showed the strongest effect in the treatment‑type experiments, though the work was done only in lab dishes, not people.
Abstract
Suppressing effect of tick-borne encephalitis (TBE) virus on expression of lymphocyte subpopulation receptors has been demonstrated in vitro. Effects of 14 immunomodulators on expression of T lymphocyte receptors under the effect of TBE virus have been compared. Anti-TBE immunoglobulin, 4-iodantipyrin, and leukinferon had the highest protective effect after a preventive injection. Thymalin and leukinferon in combination with human leukocytic interferon were the most effective within the treatment protocols. Further studies of sensitivity of immunoregulator cells to immunomodulators is recommended with the aim of adding these drugs to therapy of TBE patients.
Study Information
pubmed
2001